Metraipolis › archive › dc_fcae202e2d6e
Comparative safety analysis of Riluzole, Edaravone and Tofersen in ALS management: insights from FAERS database — Europe PMC PMID:41311831
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41311831
- DOI
- 10.3389/fphar.2025.1687698
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T15:28:52.237Z
- SHA-256 of the archived text
ac4b1426058f57127b4134dba16cfd65b8d6d699263193faf1fddb6eb22a02ef- Stable URL of this page
https://metraipolis.com/documento/dc_fcae202e2d6e
How to cite
Comparative safety analysis of Riluzole, Edaravone and Tofersen in ALS management: insights from FAERS database — Europe PMC PMID:41311831 — Europe PMC (en), https://europepmc.org/article/MED/41311831 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fcae202e2d6e (Metraipolis archive dc_fcae202e2d6e, sha256 ac4b1426058f57127b4134dba16cfd65b8d6d699263193faf1fddb6eb22a02ef)
BibTeX
@misc{dcfcae202e2d6e,
title = {Comparative safety analysis of Riluzole, Edaravone and Tofersen in ALS management: insights from FAERS database — Europe PMC PMID:41311831},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41311831},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fcae202e2d6e; sha256 ac4b1426058f57127b4134dba16cfd65b8d6d699263193faf1fddb6eb22a02ef},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41311831. Agents can read the archived copy with the MCP tool read_document.